[Molecular targeting therapy for chronic myeloid leukemia].
Kimura
Shinya
S
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D017322:Clinical Trials, Phase II as Topic; D000069439:Dasatinib; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics; D008875:Middle Aged; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000737:chemistry / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000737:chemistry / Q000627:therapeutic use*; D013844:Thiazoles / Q000737:chemistry / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; C498826:nilotinib; C506918:bafetinib; D000069439:Dasatinib